Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Asparagine SCHEMBL6514870 | 0.92 | SLC7A5 (0.37) | SLC7A5 | |
| Glutamine SCHEMBL1900122 | 0.92 | SLC7A5 (0.37) | SLC7A5 | |
| Glutamine SCHEMBL7762258 | 0.91 | — | — | |
| SCHEMBL8937067 | 0.90 | SLC7A5 (0.43) | SLC7A5 | |
| SCHEMBL8503631 | 0.86 | ITGB3 (0.32) | — | |
| Glutamine SCHEMBL14966642 | 0.81 | ALOX15 (0.38) | — | |
| Asparagine SCHEMBL3909626 | 0.79 | SLC7A5 (0.42) | SLC7A5 | |
| SCHEMBL8588120 | 0.77 | PTPN1 (0.34) | SLC7A5 | |
| SCHEMBL4575524 | 0.77 | SLC7A5 (0.56) | SLC7A5 | |
| Tyrosine SCHEMBL4292010 | 0.75 | SLC7A5 (0.45) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353171-B2 | Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2016-05-31 | — | — | US | disclosed |
| EP-3019184-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | The Administrators of the Tulane Educational Fund (US) | 2016-05-18 | — | — | EP | disclosed |
| US-20160122406-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2016-05-05 | — | — | US | disclosed |
| US-20150104388-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2015-04-16 | — | — | US | disclosed |
| WO-2014197909-A1 | ANALOGS OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND METHODS FOR THEIR USE | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140314838-A1 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS FOR TREATING CONTRAST-INDUCED NEPHROPATHY | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2014-10-23 | — | — | US | disclosed |
| EP-2533795-A2 | THE USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES | The Administrators of the Tulane Educational Fund (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120309683-A1 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2012-12-06 | — | — | US | disclosed |
| US-20110268789-A1 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2011-11-03 | — | — | US | disclosed |
| WO-2011097581-A2 | THE USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH INHIBITORS OF CALCINEURIN OR INHIBITORS OF THE MAMMALIAN TARGET OF RAPAMYCIN (mTOR) COMPLEXES | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2011-08-11 | — | — | WO | disclosed |
| EP-2337577-A1 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS | The Administrators of the Tulane Educational Fund (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010036936-A2 | USE OF PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE (PACAP) AND PACAP ANALOGS AS ADJUNCTIVE TREATMENTS WITH ANTICANCER AGENTS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-04-01 | — | — | WO | disclosed |